A fragment-based approach for the discovery of isoform-specific p38? inhibitors

In this study, we describe a novel approach for lead discovery against protein kinases, pharmacophore by interligand nuclear Overhauser effect (ILOE), in which a pair of ligands that bind to adjacent pockets on the target sur- face is identified by the detection of protein-mediated ILOEs. We demonstrate that a pharmacophore-based search guided by experimental binding data of weakly in- teracting fragments can be rapidly and efficiently used to identify (or synthesize) high-affinity, selective ligands. Targeting the inactive state of protein kinases rep- resents a promising approach to achieve selectivity and cellular efficacy. In this re- spect, when we apply the method for the discovery of potent p38 inhibitors, we also demonstrate that the resulting bidentate compounds are highly selective and exhibit a cellular activity that parallels their in vitro binding to the inactive form of the kinase. The method is relatively simple and of general applicability, and as such we anticipate its potential implementation against a variety of macromolecu- lar targets, including not only protein kinases but also those involved in protein- protein interactions or even nucleic acids.

[1]  Maurizio Pellecchia,et al.  The Nuclear Overhauser Effect in the lead identification process. , 2006, Current drug discovery technologies.

[2]  Hans Peter Nestler Combinatorial chemistry and fragment screening--two unlike siblings? , 2005, Current drug discovery technologies.

[3]  Jens Meiler,et al.  The INPHARMA method: protein-mediated interligand NOEs for pharmacophore mapping. , 2005, Angewandte Chemie.

[4]  J. Boehm,et al.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases , 2003, Nature Reviews Drug Discovery.

[5]  R. Griffey,et al.  SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets. , 2002, Journal of medicinal chemistry.

[6]  Maurizio Pellecchia,et al.  Targeting apoptosis via chemical design: inhibition of bid-induced cell death by small organic molecules. , 2004, Chemistry & biology.

[7]  Markus Schade,et al.  NMR fragment screening: tackling protein-protein interaction targets. , 2005, Current opinion in drug discovery & development.

[8]  W. Patrick Walters,et al.  A guide to drug discovery: Designing screens: how to make your hits a hit , 2003, Nature Reviews Drug Discovery.

[9]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[10]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[11]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[12]  M. Uesugi,et al.  [Discovering high-affinity ligands for proteins: SAR by NMR]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[13]  J. Madwed,et al.  Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. , 2002, Journal of medicinal chemistry.

[14]  Christopher W Murray,et al.  Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.

[15]  L. Tong,et al.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.

[16]  Jerry L. Adams,et al.  A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.

[17]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[18]  Daniel A. Erlanson,et al.  Fragment‐Based Drug Discovery. , 2004 .

[19]  Maurizio Pellecchia,et al.  Solution nuclear magnetic resonance spectroscopy techniques for probing intermolecular interactions. , 2005, Chemistry & biology.

[20]  E. Jaeger,et al.  Comparison of automated docking programs as virtual screening tools. , 2005, Journal of Medicinal Chemistry.

[21]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[22]  J. Irwin,et al.  ZINC ? A Free Database of Commercially Available Compounds for Virtual Screening. , 2005 .

[23]  Ajay,et al.  The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. , 1999, Chemistry & biology.

[24]  B. Shoichet,et al.  High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.

[25]  Johan Schultz,et al.  Structure-based screening as applied to human FABP4: a highly efficient alternative to HTS for hit generation. , 2002, Journal of the American Chemical Society.

[26]  D E Griswold,et al.  Inhibition of p38 MAP kinase as a therapeutic strategy. , 2000, Immunopharmacology.

[27]  Maurizio Pellecchia,et al.  Structure–activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid , 2006, Proceedings of the National Academy of Sciences.

[28]  Maurizio Pellecchia,et al.  SAR by ILOEs: an NMR-based approach to reverse chemical genetics. , 2006, Chemistry.

[29]  Vicki L. Nienaber,et al.  Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.